Sevirumab
From Self-sufficiency
| Monoclonal antibody | |
|---|---|
| Type | ? |
| Source | Template:Infobox drug/mab source |
| Target | CMV |
| Identifiers | |
| ATC code | none |
Sevirumab (MSL-109) is a human monoclonal antibody for the treatment of infections with cytomegalovirus in patients with AIDS.[1][2]
References
Cite error: Invalid <references> tag;
parameter "group" is allowed only.
<references />, or <references group="..." />
| 40x30px | This monoclonal antibody-related article is a stub. You can help ssf by expanding it. |
- ↑ Borucki, MJ; Spritzler, J; Asmuth, DM; Gnann, J; Hirsch, MS; Nokta, M; Aweeka, F; Nadler, PI; Sattler, F (2004). "A phase II, double-masked, randomized, placebo-controlled evaluation of a human monoclonal anti-Cytomegalovirus antibody (MSL-109) in combination with standard therapy versus standard therapy alone in the treatment of AIDS patients with Cytomegalovirus retinitis". Antiviral research. 64 (2): 103–11. doi:10.1016/j.antiviral.2004.06.012. PMID 15498605.
- ↑ ClinicalTrials.gov
Categories:
- Pages with script errors
- Articles which use infobox templates with no data rows
- Drugs that are a monoclonal antibody
- Infobox drug tracked parameters
- Chemical articles without CAS Registry Number
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs not assigned an ATC code
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- 2Fix
- Pages with broken file links
- Monoclonal antibody stubs
